
ACS Central Science, Journal Year: 2024, Volume and Issue: 10(8), P. 1594 - 1608
Published: July 25, 2024
The combined inhibition of endoplasmic reticulum (ER) α-glucosidases I and II has been shown to inhibit replication a broad range viruses that rely on ER protein quality control. We found, by screening panel deoxynojirimycin cyclitol glycomimetics, the mechanism-based α-glucosidase inhibitor, 1,6-epi-cyclophellitol cyclosulfate, potently blocks SARS-CoV-2 in lung epithelial cells, halting intracellular generation mature spike protein, reducing production infectious progeny, leading reduced syncytium formation. Through activity-based profiling, we confirmed primary airway grown at air–liquid interface. 1,6-epi-Cyclophellitol cyclosulfate inhibits early pandemic more recent variants, as well SARS-CoV MERS-CoV. reported antiviral activity is comparable best-in-class described glucosidase inhibitors, all competitive inhibitors also targeting other glycoprocessing enzymes not involved propose selective blocking ER-resident covalent irreversible manner new strategy search for effective agents
Language: Английский